Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 90 P409 | DOI: 10.1530/endoabs.90.P409

1Fondazione Policlinico Universitario A. Gemelli, Endocrinology and Diabetology, Roma, Italy; 2Fondazione Policlinico Universitario A. Gemelli, Traslational Medicine, Roma, Italy; 3Fondazione Policlinico Universitario A. Gemelli, Women’s and Children’s health sciences and Public health, Roma, Italy; 4Fondazione Policlinico Universitario A. Gemelli, Neurosurgery, Roma, Italy


Introduction: Somatotropinomas are benign pituitary tumors with heterogeneous biological and clinical behavior. The tumor microenvironment (TME) is an environment generated by the interaction between tumor cells and the host immune system. It affects both the behavior of the tumor and the outcome of the therapy. The GNAS gene encodes the alpha subunit of G proteins associated with hormone receptors such as TSH, PTH, GHRH, FSH/lH, ACTH. Mutation of this gene has been associated with more aggressive forms of acromegaly. We aim to investigate the presence of CD3+, CD20+, CD138+, CD4+, CD8+, CD68+ cells in the tumor inflammatory infiltrate and their correlation with GNAS mutations.

Material and methods: A retrospective, monocenter study was conducted on 36 acromegaly pts included according the following criteria: 1) age >18 at the diagnosis of acromegaly, 2) availability of tumor sample. Pts with history of radiotherapy of head/neck within 10 years before pituitary surgery, with immune-related disease were ruled out.

Results: Thirty-six patients (23 females) entered the study. Macro-adenomas were identified in 23 cases (12 with cavernous sinus invasion). The median value of tumor infiltrating CD3+ lymphocytes was 30/HPF (IQR: 41.7, range: 7-122), of CD20+ lymphocytes was 2.5/HPF (IQR: 2.75, range: 0.5-12), of CD138+ was 6.5/HPF (IQR: 7.75, range: 1-44), of CD4+ lymphocytes was 5/HPF (IQR: 5.5), of CD8+ lymphocytes was 21/HPF (IQR: 29.5) and of CD68+ macrophages was 50/HPF (IQR: 30). CD68+/CD4+ ratio was 2.4 (IQR: 4.8). Four patients carried GNAS mutations. The number of CD3+, CD20+, CD138+, CD4+, CD8+, CD68+ was similar among GNAS wild type and not-wild type patients.

Conclusion: According to our preliminary data, GNAS mutation do not modify TME in somatotropinomas.

Volume 90

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.